-
EP3194450
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3194450
| EP3194450 - MULTIVALENT FRAGMENTS OF ANTIBODY 3E10 AND METHODS OF USE THEREOF [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 25.11.2022 Database last updated on 11.04.2026 | |
| Former | Examination is in progress Status updated on 10.07.2020 | ||
| Former | Request for examination was made Status updated on 23.06.2017 | ||
| Former | The international publication has been made Status updated on 17.02.2017 | Most recent event Tooltip | 25.11.2022 | Withdrawal of application | published on 28.12.2022 [2022/52] | Applicant(s) | For all designated states Yale University Two Whitney Avenue New Haven, CT 06510 / US | For all designated states The United States Government as represented by The Department of Veterans Affairs 810 Vermont Avenue, N.W. Washington, DC 20420 / US | [2017/30] | Inventor(s) | 01 /
HANSEN, James E. 70 Squaw Lane Guilford, CT 06437 / US | 02 /
WEISBART, Richard H. 9621 Lockford Street Los Angeles, CA 90035 / US | 03 /
NOBLE, Philip W. 2 Duke Street Windsor Berkshire SL4 1SA / GB | [N/P] |
| Former [2017/30] | 01 /
HANSEN, James E. 70 Squaw Lane Guilford, CT 06437 / US | ||
| 02 /
WEISBART, Richard H. 9621 Lockford Street Los Angeles, CA 90035 / US | |||
| 03 /
NOBLE, Philip W. 128 Edwards Street Apt. 3 New Haven, CT 06511 / US | Representative(s) | Potter Clarkson Chapel Quarter Mount Street Nottingham NG1 6HQ / GB | [N/P] |
| Former [2017/30] | Potter Clarkson LLP The Belgrave Centre Talbot Street Nottingham NG1 5GG / GB | Application number, filing date | 15760023.0 | 27.08.2015 | [2017/30] | WO2015US47174 | Priority number, date | US201462043228P | 28.08.2014 Original published format: US 201462043228 P | [2017/30] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016033321 | Date: | 03.03.2016 | Language: | EN | [2016/09] | Type: | A1 Application with search report | No.: | EP3194450 | Date: | 26.07.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 03.03.2016 takes the place of the publication of the European patent application. | [2017/30] | Search report(s) | International search report - published on: | EP | 03.03.2016 | Classification | IPC: | C07K16/44, A61P35/00 | [2017/30] | CPC: |
C07K16/44 (EP,US);
A61K39/39583 (US);
A61K45/06 (US);
A61P31/12 (EP);
A61P31/14 (EP);
A61P35/00 (EP);
A61P35/02 (EP);
A61P43/00 (EP);
A61K2039/505 (EP,US);
C07K2317/35 (EP,US);
C07K2317/56 (US);
C07K2317/565 (US);
C07K2317/622 (EP,US);
C07K2317/624 (US);
C07K2317/626 (US);
C07K2317/73 (EP,US);
C07K2317/76 (US);
C07K2317/77 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/30] | Title | German: | MULTIVALENTE FRAGMENTE VON ANTIKÖRPER 3E10 UND VERFAHREN ZUR VERWENDUNG DAVON | [2017/30] | English: | MULTIVALENT FRAGMENTS OF ANTIBODY 3E10 AND METHODS OF USE THEREOF | [2017/30] | French: | FRAGMENTS MULTIVALENTS D'ANTICORPS 3E10 ET SES PROCÉDÉS D'UTILISATION | [2017/30] | Entry into regional phase | 16.02.2017 | National basic fee paid | 16.02.2017 | Designation fee(s) paid | 16.02.2017 | Examination fee paid | Examination procedure | 16.02.2017 | Examination requested [2017/30] | 16.02.2017 | Date on which the examining division has become responsible | 05.10.2017 | Amendment by applicant (claims and/or description) | 14.07.2020 | Despatch of a communication from the examining division (Time limit: M06) | 22.12.2020 | Reply to a communication from the examining division | 24.11.2022 | Application withdrawn by applicant [2022/52] | 02.02.2023 | Date of oral proceedings | Fees paid | Renewal fee | 22.08.2017 | Renewal fee patent year 03 | 27.08.2018 | Renewal fee patent year 04 | 27.08.2019 | Renewal fee patent year 05 | 27.08.2020 | Renewal fee patent year 06 | 27.08.2021 | Renewal fee patent year 07 | 29.08.2022 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XAI] WO2012135831 (UNIV YALE et al.) | [XI] WO2012145125 (4S3 BIOSCIENCE INC et al.) | [A] CUESTA A M ET AL: "Multivalent antibodies: when design surpasses evolution", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 28, no. 7, 1 July 2010 (2010-07-01), pages 355 - 362, XP027102411, ISSN: 0167-7799, [retrieved on 20100504] | [A] JAIN ET AL: "Engineering antibodies for clinical applications", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 25, no. 7, 1 July 2007 (2007-07-01), pages 307 - 316, XP022116341, ISSN: 0167-7799 | [A] DEYEV SERGEY M ET AL: "Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design", BIOESSAYS, CAMBRIDGE; GB, vol. 30, no. 9, 1 September 2008 (2008-09-01), pages 904 - 918, XP002663706, ISSN: 0265-9247, DOI: 10.1002/BIES.20805 DOI: http://dx.doi.org/10.1002/bies.20805 | [A] ZACK D J ET AL: "DNA MIMICS A SELF-PROTEIN THAT MAY BE A TARGET FOR SOME ANTI-DNA ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 154, 1 January 1995 (1995-01-01), pages 1987 - 1994, XP002063314, ISSN: 0022-1767 | [A] HANSEN ET AL: "Antibody mediated transduction of therapeutic proteins into living cells", THE SCIENTIFIC WORLD, THE SCIENTIFICWORLD LTD, GB, vol. 5, no. 9, 16 September 2005 (2005-09-16), pages 782 - 788, XP008110943, ISSN: 1532-2246, DOI: 10.1100/TSW.2005.98 DOI: http://dx.doi.org/10.1100/tsw.2005.98 | [AD] HANSEN J E ET AL: "Targeting Cancer with a Lupus Autoantibody.", SCIENCE TRANSLATIONAL MEDICINE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC, vol. 4, no. 157, 24 October 2012 (2012-10-24), pages 155 - 161, XP008176380, ISSN: 1946-6234, DOI: 10.1126/SCITRANSLMED.3004385 DOI: http://dx.doi.org/10.1126/scitranslmed.3004385 | [A] MENGYUAN LIU ET AL: "A novel bivalent single-chain variable fragment (scFV) inhibits the action of tumour necrosis factor [alpha]", BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, vol. 50, no. 4, 1 August 2008 (2008-08-01), US, pages 173 - 179, XP055225197, ISSN: 0885-4513, DOI: 10.1042/BA20070229 DOI: http://dx.doi.org/10.1042/BA20070229 | Examination | US2013266570 | by applicant | US4812397 | US7189396 | US2014050723 | SCOTT ET AL., NATURE REVIEWS CANCER, vol. 12, 2012, pages 278 - 287 | HANSEN ET AL., SCIENCE TRANSLATIONAL MEDICINE, vol. 4, 2012, pages 157RA142 | WEISBART ET AL., J AUTOIMMUN., vol. 11, 1998, pages 539 - 546 | WEISBART ET AL., INT. J ONEOL., vol. 25, 2004, pages 1867 - 1873 | PUC ET AL., CELL CYCLE, vol. 4, 2005, pages 927 - 929 | BASSI ET AL., SCIENCE, vol. 341, 2013, pages 395 - 399 | KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH | CHOTHIA; LESK, J MOL. BIOL., vol. 196, 1987, pages 901 - 917 | HANSEN ET AL., SCIENCE TRNNSLNTIONNL MEDICINE, vol. 4, 2012, pages 157RA142 | ZACK ET AL., IMMUNOLOGY AND CELL BIOLOGY, vol. 72, 1994, pages 513 - 520 | WEISBART, INT. J. ONCOL., vol. 25, 2004, pages 1867 - 1873 | ZACK ET AL., J. IMMUNOL., vol. 154, no. 4, 15 December 1994 (1994-12-15), pages 1987 - 94 | ZACK ET AL., IMMUNOLOGY AND CELL BIOLOGI,, vol. 72, 1994, pages 513 - 520 | KABOURIDIS, P., TRENDS IN BIOTECHNOLOGY, 2003, pages 498 - 503 | FRANKEL; PABO, CELL, vol. 55, no. 6, 1988, pages 1189 - 93 | DEROSSI ET AL., J. BIOL. CHEM., vol. 269, no. 14, 1994, pages 10444 - 50 | WENDER ET AL., PI-OC. NATL. ACAD. SCI. USA, vol. 97, no. 24, 2000, pages 13003 - 8 | HO ET AL., CANCER RES., vol. 61, no. 2, 2001, pages 474 - 7 | BARKA ET AL., HISTOCHENI. VTOEHEM.,, vol. 48, no. 11, 2000, pages 1453 - 60 | WADIA; STAN, NAT. MED., vol. 10, no. 3, 2004, pages 310 - 5 | YODER ET AL., PLOS ONE, 6 March 2011 (2011-03-06), pages EL7862 | LAU ET AL., NAT CELL BIOL, vol. 7, no. 5, 2005, pages 493 - 500 | WEISBART ET AL., INT. J ONCOL., vol. 25, 2004, pages 1113 - 1118 | HANSEN ET AL., BRAIN RES., vol. 1088, 2006, pages 187 - 196 | HANSEN ET AL., J. BIOL. CHEM., vol. 282, 2007, pages 20790 - 20793 | ZHAN ET AL., STROKE, vol. 41, 2010, pages 538 - 543 | HUCL ET AL., CANCER RES., vol. 68, 2008, pages 5023 - 5030 | MCCABE ET AL., CANCER BIOLOGY & THERAPY, vol. 4, 2005, pages 934 - 936 | PUC ET AL., CELL CYCLE, vol. 4, 2005, pages 927 - 9 | BASSI ET AL., SCIENCE, vol. 341, 2013, pages 395 - 9 | MCELLIN ET AL., CANCER RES., vol. 70, 2010, pages 5457 - 64 | HANSEN ET AL., SCIENCE TRANSLATIONAL MEDICINE, vol. 4, 2012, pages 157RA42 | CLEAVER ET AL., CELL CYCLE, vol. 10, 2011, pages 3223 - 4 | LEVITT ET AL., BIOEHEM BIOPHYS RES COMMUN.,, vol. 336, 2005, pages 1056 - 61 | HUCL ET AL., CANCER RES., vol. 68, 2008, pages 5023 - 30 | MCCABE ET AL., CANCER BIOLOGY & THERAPY, vol. 4, 2005, pages 934 - 6 | KELLNER ET AL., METHODS, vol. 65, 2014, pages 105 - 113 | KANE ET AL., CANCER RES., vol. 57, 1997, pages 808 - 811 | VLIETSTRA ET AL., CANCER RES., vol. 58, 1998, pages 2720 - 2723 | STECK ET AL., NAT. GENET., vol. 15, 1997, pages 356 - 362 | LI ET AL., SCIENCE, vol. 275, 1997, pages 1943 - 1947 | JANG ET AL., PHARM. RES., vol. 20, 2003, pages 1337 - 1350 | MAEDA ET AL., JOURNAL OF CONTROLLED RELEASE : OFFICIAL JOURNAL OF THE CONTROLLED RELEASE SOCIETY, vol. 65, 2000, pages 271 - 284 |